News broke on Friday that Citigroup (NYSE: C ) may have to go back into court to refight a case that could cost it $8.3 billion. As expected, the market is showing its displeasure, with shares of the superbank opening tentatively in the green today, but now decidedly into the red.
Back on Terra Firma, unfortunately
The case involves the 2007 purchase of recording and publishing giant EMI by British financier Guy Hands and his private equity fund, Terra Firma Capital. Citi was Terra Firma's banker for the $6.8 billion transaction.
In his $8.3 billion suit, Hands alleged that a Citi investment banker lied about another bidder, which resulted in Terra Firma grossly overpaying for EMI. The case went to court, and Citi won, but now a federal appeals judge has overturned the jury verdict, citing that "improper jury instructions from the [original] trial court judge required a reversal," according to The New York Times.�
Look ma, no financial crisis!
This potential payout is unusual in at least one regard -- it's not related to the financial crisis. Whether it's Citigroup, Bank of America, JPMorgan Chase, or Wells Fargo, when you hear about a multi-billion dollar payout anymore, you automatically assume it relates back to the financial crisis. And 99 times out of 100, you're right.
Top 5 Forestry Stocks To Buy For 2015: CEVA Inc.(CEVA)
CEVA, Inc., together with its subsidiaries, engages in licensing silicon intellectual property (SIP) for the handsets, mobile broadband, portable, and consumer electronics markets primarily in the United States, Europe, the Middle East, and the Asia Pacific. It designs and licenses DSP cores in the form of a hardware description language definition; a portfolio of application-specific platforms, including wireless baseband, audio, imaging and vision, voice over Internet protocols (VoIP), Bluetooth, and serial storage technology and serial attached SCSI; and development platforms, software development kits, and software debug tools that facilitate system design, debug, and software development. The company?s intellectual property (IP) is used by semiconductor and original equipment manufacturer companies for application-specific integrated circuits and application-specific standard products. It serves various markets, including feature phones, smartphones, machine to machi ne for various cellular standards, home entertainment, portable game consoles, and serial storage and telecommunication devices. CEVA, Inc. markets its technology through a direct sales force. The company was formerly known as ParthusCeva, Inc. and changed its name to CEVA, Inc. in December 2003. CEVA, Inc. was founded in 1999 and is headquartered in Mountain View, California.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on CEVA (Nasdaq: CEVA ) , whose recent revenue and earnings are plotted below.
5 Best Dow Dividend Stocks To Invest In Right Now: Zogenix Inc (ZGNX)
Zogenix, Inc. (Zogenix), incorporated on May 11, 2006, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company�� product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. Sumavel DosePro and Zohydro are used for the treatment options available to patients and physicians in the United States. Sumavel DosePro may serve as a treatment alternative to oral and nasal triptans and offers administration when compared to traditional, needle-based sumatriptan injection. In May, 2012, it submitted a New Drug Application to the Food and Drug Administration (FDA).
The Company�� collaboration with Astellas has been terminated on March 31, 2012. Sumavel DosePro is a pre-filled, single-use disposable, needle-free drug delivery system that subcutaneously delivers 6 mg of sumatriptan in 0.5 mL of sterile liquid. Sumavel DosePro is designed to be portable, intuitive and easy-to-use. To use, the patient simply snaps off a plastic tip, flips back a lever and presses the end of the delivery system to the skin of the abdomen or thigh. Under the force of a small amount of compressed nitrogen gas, the liquid form of sumatriptan is expelled out of the device as a thin jet of medication, which pierces the skin and selectively deposits into the subcutaneous tissue.
Zogenix competes with GlaxoSmithKline, AstraZeneca PLC, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., ! Inc., Pfizer Inc., Alexza Pharmaceuticals, Inc., MAP Pharmaceuticals, Inc., Abbott Laboratories, Alpharma Inc., Endo Pharmaceuticals Holdings Inc., King Pharmaceuticals, Inc., Mallinckrodt Inc., Purdue Pharma L.P., Teva Pharmaceutical Industries Limited, Watson Pharmaceuticals, Inc., Becton, Dickinson and Company, Owen Mumford Ltd., Ypsomed, Sandoz Inc., Bioject Inc. and Antares Pharma Inc.
Advisors' Opinion:- [By Lauren Pollock]
The Food and Drug Administration approved an extended-release version of the narcotic painkiller hydrocodone despite a recommendation by its advisory committee that the drug should be rejected because of its potential for abuse. The federal agency approved Zohydro ER from Zogenix Inc.(ZGNX), the first hydrocodone product not mixed with milder painkillers such as acetaminophen and also the first extended-release hydrocodone product. Shares rose 15% to $3.49 premarket.
- [By Monica Gerson]
Zogenix (NASDAQ: ZGNX) shares gained 9.21% to $3.32 in the pre-market session after the company won the FDA approval for Zohydro ER capsules.
Ariad Pharmaceuticals (NASDAQ: ARIA) soared 5.06% to $3.74 in the pre-market trading. ARIAD Pharmaceuticals is expected to report its Q3 financial results on November 6, 2013.
5 Best Dow Dividend Stocks To Invest In Right Now: Nicholas Financial Inc.(NICK)
Nicholas Financial, Inc., through its subsidiaries, operates as a specialized consumer finance company. The company engages in acquiring and servicing contracts for purchases of new and used automobiles and light trucks. It also makes direct loans and sells consumer-finance related products. In addition, the company engages in developing, marketing, supporting, and updating industry-specific computer application software for small businesses located primarily in the Southeast United States. As of April 5, 2011, it operated 56 branch locations in 14 Southeastern and Midwestern states. The company was founded in 1986 and is headquartered in Clearwater, Florida.
Advisors' Opinion:- [By Lauren Pollock]
Prospect Capital Corp.(PSEC) said it agreed to buy Nicholas Financial Inc.(NICK) in a stock deal valued at about $199 million that the investment firm expects will expand its presence in the car-loan industry. Prospect Capital is offering $16 a share for Nicholas, a 4.5% premium over Tuesday’s closing price. Nicholas Financial shares edged up 2.8% to $15.70 premarket.
5 Best Dow Dividend Stocks To Invest In Right Now: Cadence Pharmaceuticals Inc.(CADX)
Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on acquiring, in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada. It holds rights to OFIRMEV injection, a proprietary intravenous formulation of acetaminophen for the management of pain and reduction of fever in adults and children. The company in-licenses rights to OFIRMEV from Bristol-Myers Squibb Company, which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the Perfalgan brand name. Cadence Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Cadence Pharmaceuticals (NASDAQ: CADX) shot up 26.42 percent to $14.02 after Mallinckrodt plc (NYSE: MNK) announced its plans to acquire Cadence Pharma for $14.00 per share in cash.
No comments:
Post a Comment